ALKERMES PLC. (ALKS)
Alkermes to Present Additional Data From Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at the American Academy of Neurology (AAN) 2026 Annual Meeting
Alkermes to Present Additional Data From Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at the American Academy of Neurology (AAN) 2026 Annual Meeting
📈 **POSITIVE** • Medium confidence analysis (78%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business